WE ARE ON THE WAY TO CREATING A BIOTECHNOLOGY COMPANY FOCUSED ON TRULY INNOVATIVE THERAPIES , A PIONEERING APPROACH IN THE BRAZILIAN PHARMACEUTICAL INDUSTRY .
INDUSTRY WATCH
WE ARE ON THE WAY TO CREATING A BIOTECHNOLOGY COMPANY FOCUSED ON TRULY INNOVATIVE THERAPIES , A PIONEERING APPROACH IN THE BRAZILIAN PHARMACEUTICAL INDUSTRY .
After an initial investment of US $ 3m in 2022 , Nintx ( Next Innovative Therapeutics ), a biotechnology company that researches and develops treatments for complex or multifactorial diseases using Brazil ’ s biodiversity , has just raised another US $ 10m .
The investments will serve to support the company ’ s plans for the coming years , which include accelerating the R + D of eight new drug programs ( most in collaboration with companies such as Adeste and Centroflora , and research institutions such as CIEnP and CNPEM , which hosts Sirius , one of the world ’ s largest particle accelerators ), the recruitment of researchers , the introduction of new technologies and the expansion of the laboratory .
Nintx has an innovative approach to addressing multifactorial diseases caused by genetic and environmental factors , as well as their interactions , especially those mediated by the human gut microbiome . The biotechnology focuses on multi-target therapies and leverages proprietary technologies such as xGI biomics , which simulates the gastrointestinal system , and GAIA path , a knowledge graph data analysis platform that traces connections between plants , natural products , biological targets , the human microbiome and multifactorial diseases .
Nintx ’ s business model is to advance therapies until the end of preclinical studies , at which point it plans to license large pharmaceutical companies for clinical development and commercialization . The team expects the first drug candidate to be licensed within three years .
Investors in the Series A round include venture capital firms Pitanga , Ecoa Capital and MOV Investimentos . Strategic partners Tiaraju and Adeste also joined the investments with the aim of strengthening synergies between their businesses and Nintx .
Guilherme Leal , co-founder of Natura and Dengo , and Peter Andersen , of Centroflora , are still shareholders .
The Series A funds ( unprecedented for a biotechnology startup in the Brazilian pharmaceutical sector ) are complemented by a grant of USD 2.5 million from FINEP , a public company that promotes and finances science , technology and innovation .
“ In the US and Europe , biopharma startups that start licensing innovative drugs to Big Pharma can reach valuations in the hundreds of millions of dollars . We believe that Nintx has the potential to follow the same trajectory ,” said Gabriel Pérez , from Pitanga .
“ Something that struck us deeply was the potential for social and environmental impact of Nintx , as it values biodiversity through agroforestry practices , investments in smallholder farmers and benefit-sharing agreements with communities that have knowledge about these plants ,” said Paulo Bellotti of MOV Investimentos .
New leadership
The financing coincides with a restructuring of Nintx ’ s management . Stephani Saverio , co-founder of the company together with scientists Miller Freitas and Cristiano Guimarães , took over as CEO in January 2025 . Previously a member of the Board of Directors , Saverio now plays an executive role .
With more than 25 years of experience in large pharmaceutical groups , Saverio leaves the position of Global Vice President of Business Development at Knight Therapeutics , a Pan-American specialty pharmaceutical company , to take on the challenge at Nintx .
www . intelligentcio . com INTELLIGENTCIO LATAM 61